🩺 Clinical case preview - tonight’s #EASLMTB!
A 75-year-old male with HCV-related cirrhosis and a new 57 mm sVIII nodule with vascular invasion.
👉 Diagnosis: hepatocellular carcinoma. How will he respond to treatment? What will happen next?
🚨 Register and join the experts' discussion in 30 minutes!
https://t.co/lQtWpGUmpD
@EASLnews@MarcoSanduzzi@VChernyakMD@siadaniela@Vaital73
#EASLMTB #LiverX
Thank you to our amazing panel! 🙏✨
@ma5RN@MarcoSanduzzi@VChernyakMD@siadaniela@Vaital73
Join us next January in Edinburgh for an in-person #EASLMTB episode at the EASL Liver Cancer Summit 2026:
📅 Friday, 23 January 2026 | 10:05 CET
🔗 Event link: https://t.co/d0oibByz3F
👉 EASL LCS 2026 registration link: https://t.co/PeLI1pi3Kv
@EASLnews #LiverX
Concordance of ctDNA and tissue genomic profiling in biliary tract cancer
@JHepatology
https://t.co/i53bksEIxs
👉concordance in 84.8%,
👉ctDNA revealed 🎯GA in 34.3%
👉high VAF in ctDNA associated w/ poor prognosis
🧐LB valuable option
@myESMO@EASLedu@ILCAnews@curecc #livertwitter
Our review on "Morphomolecular pathology and Genomic Insights into the Cells of Origin of Cholangiocarcinoma and combined Hepatocellular-Cholangiocarcinoma" was recently released in Am J Pathol @siadaniela
https://t.co/98q8gd4QDD
Struggling to balance your research with the fast-paced world of social media? You're not alone. Join Sarah Cappuyns at #ILCA24 for our dedicated session to learn the advantages and challenges of using social media in your scientific research.
👀 https://t.co/NMckE9JK8f
On June 1, 2024, we proudly joined the Liver Life Walk NYC with 34 teams and 294 walkers. Huge thanks to Dr. Douglas Dieterich, this year's Medical Chair. Grateful to everyone who participated and supported us.
#LiverLifeWalk#Gratitude#ALF@DOMSinaiNYC@liverUSA
Grateful to the scientific community, @staclinds, Juan Valle, and a wonderful co-chair @siadaniela for making the first Basic Science Track at @curecc Annual Conference a huge success. We had remarkable speakers from all over the world in a packed room with robust discussion.
The Genetic and Epigenetic Drivers of CCA session at @curecc was a great session with a lively discussion covering:
👉🏼 cancer epigenomics at the single cell level
👉🏼 germine genetics and CCA risk
👉🏼 genetics of CCA subtypes
👉🏼 tumor genotype-immune phenotype relationship
We are looking for a post-doctoral fellow to join our research group at Mount Sinai in New York City.
Required experience with mice, friendly and teamworker.
To apply:
https://t.co/L77HF2UNwO
Seeking a motivated post-doc to study novel mouse models of cholangiocarcinoma with KRASG12D mutations. Help us explore how KRAS impacts the immune response and therapy outcomes. Apply now: https://t.co/KxEkMHCU1C #CancerResearch#PostDocJobs#NYC#WeFindAWay@DOMSinaiNYC
We are looking for a post-doctoral fellow to join our research group at Mount Sinai in New York City.
Required experience with mice, friendly and teamworker.
To apply:
https://t.co/L77HF2UNwO
#EASLStudio:
👉Check regularly the treatment response
👉 Immune check point inhibitors ➡️ have limited effect alone
👉 Do biopsy as much as possible
👉 Molecular profiling (DNA+RNA seq) for fusion & liquid biopsy for mutation identification
🧐 % of 5-yrs survival remains low